Tianjin Development (00882.HK): Ordered pharmaceutical business raised target price to 9 yuan
Tianjin Development (0882.HK): Xiongan concept's premium is close to zero; mixed reform is the next focus
Goldman Sachs Group gives buy ratings to 00363.HK (Shanghai Stock Exchange) and Fosun (00656.HK)
Merrill Lynch: Tianjin Development (00882.HK) received an order for pharmaceutical business and raised the target price to 9 yuan
Goldman Sachs gave Tianjin Development (00882-HK) a purchase rating for the first time, with a target price of HK$4.70
Dafu: Tianjin Development (0882.HK) has the potential to be re-rated.
Tai Fook maintains its buy rating on Tianjin Development (0882.HK) with a target price of HK $5.90.
GC maintains Tianjin Development (0882.HK) buying rating; A-shares may be listed
Merrill Lynch raised the target price of Tianjin Development (0882.HK) to HK$6.50
Goldman Sachs raised the target price of Tianjin Development (0882.HK) to HK$3.1
美林将天津发展(0882.HK) 目标价下调至4.1港元
Dafu expects Tianjin Development (00882-HK) to be seriously underestimated, looking at HK$5.2
申万评天津发展(00882-HK)买入,高看3.92港元
Tianjin Development (0882-HK): Results for the first half of 2007 were in line with expectations, and the company announced a new potential acquisition plan with a neutral rating
Tianjin Development: covering stocks with reasonable valuation for the first time
No Data